Business
NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response
FT. MYERS, FL / ACCESSWIRE / December 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced new data
About this update from Neogenomics, Inc.
[{"type":"text","content":"FT. MYERS, FL / ACCESSWIRE / December 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced new data highlighting its RaDaR® assay for minimal residual disease (MRD) will be presented at the 46th annual San Antonio Breast Cancer Symposium (SABCS). RaDaR data will be presented during a Poster Spotlight Session featuring an updated analysis of the TRACER study, which assessed patients with early-stage breast cancer across multiple subtypes and the potential utility of using RaDaR in this setting, including for baseline detection, for monitoring therapy response in the neoadjuvant setting, and for post-operative recurrence monitoring.\"The TRACER data continues to demonstrate the value of RaDaR technology, especially in excellent baseline detection of circulating tumor DNA to facilitate therapy response monitoring before and during neoadjuvant therapy,\" said Vishal Sikri, President of Advanced Diagnostics at NeoGenomics. \"Evaluating therapy response is essential to cancer care, enabling patients and their physicians to make more informed treatment decisions that may improve cancer outcomes.\"Details of NeoGenomics' presentations at SABCS 2023 are outlined below.Wednesday, December 6, 7:00 AMLongitudinal Neoadjuvant and Post-operative Evaluation of Circulating Tumor DNA in Early Breast Cancer using a Tumor-Informed Assay: Updated Analysis of the TRACER Cohort - Mitchell Elliott, MD, Princess Margaret Cancer Centre, University of Toronto, et al.Wednesday, December 6, 5:00 PMNovel Metrics of HER2 Heterogeneity in HER2-Positive and HER2-Low Breast Cancer via High Dimensional Multiplexed Immunofluorescence Spatial Profiling - Daniel G. Stover, MD, The Ohio State University Comprehensive Cancer Center, et al.NeoGenomics is also excited to announce receipt of the first samples from the SURVIVE clinical trial, a large multi-site, prospectively randomized study in collaboration with the University of Ulm, Germany, that utilizes RaDaR for recurrence monitoring and potential intervention across sub-types of breast cancer (NCT05658172).About RaDaR® TechnologyThe RaDaR assay is a personalized, tumor-informed, highly sensitive technology that tracks a set of up to 48 tumor-specific variants in cell-free DNA (cfDNA) within a cancer patient's blood plasma. Built on the proven InVision platform, th...